Coronavirus Disease-2019 (COVID-19): An Updated
                    Review

Mithun Rudrapal; Shubham J. Khairnar; Laxmikant B. Borse; Anil G. Jadhav

doi:10.1055/a-1217-2397

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2020; 70(09): 389-400
DOI: 10.1055/a-1217-2397

Review

Coronavirus Disease-2019 (COVID-19): An Updated Review

Mithun Rudrapal

¹Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India

,

Shubham J. Khairnar

¹Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India

,

Laxmikant B. Borse

¹Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India

,

Anil G. Jadhav

¹Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India

› Institutsangaben

Abstract

The current outbreak of novel Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major pandemic situation and a catastrophe for humans. COVID-19 is a severe infectious disease particularly of the respiratory system characterized by fatal complications such as severe acute respiratory distress syndrome (SARS), pneumonia, cardiac arrhythmia, kidney failure/ multiple organ failure and even death. Since its discovery, the SARS-CoV-2 has spread across 213 countries or territories, causing more than 8.5 million people with a rising death toll over 5.5 million people (as of June 2020, WHO). In fact, the current looming crisis of COVID-19 has become an increasingly serious concern to public health. It has affected lives of millions of people with severe impact on health systems and economies globally. Since there are no specific drugs and/or vaccines available so far, combating COVID-19 remains to be a major challenging task. Therefore, development of potential and effective treatment regimens (prophylactic/therapeutic) is urgently required which could resolve the issue. In this review, we summarize the current knowledge about the coronavirus, disease epidemiology, clinical manifestations and risk factors, replication of the virus, pathophysiology and host immune responses of SARS-CoV-2 infection. The therapeutic interventions and prophylactic measures along with precautionary measures are the frontline approaches that could be undertaken in order to control and prevent the spread of the deadly and highly contagious COVID-19 are also detailed herein.

Key words

Coronavirus - COVID-19 - SARS-CoV-2 - Pneumonia - Respiratory infection - Anti-retrovial

Volltext

Referenzen

References
1 Coronavirus disease (COVID-19 Pandemic). Available from URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019; (accessed on 17/06/2020)
2 COVID-19: Prevention & Investigational Treatments. Available from URL: https://www.drugs.com/condition/covid-19.html; (accessed on 19/06/2020)
3 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 1-10
4 Yi Y, Lagniton PNP, Ye S. et al. COVID-19: What has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020; 16: 1753-1766
5 Wang L, Wang Y, Ye D. et al. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents 2020;
6 Chatterjee P, Nagi N, Agarwal A. et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020; 151: 147-159
7 Docea AO, Tsatsakis A, Albulescu D. et al. A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med 2020; 45: 1631-43
8 Kumar D, Malviya R, Sharma PK. Corona virus: A review of COVID-19. Eurasian. J Med Oncol 2020; 4: 8-25
9 Yuen KS, Ye ZW, Fung SY. et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 1-5
10 Coronavirus (COVID-19). Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/index.html; (accessed on 18/06/2020)
11 Tang X, Wu C, Li X. et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020;
12 Hassan SA, Sheikh FN, Jamal S. et al. Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment. Cureus 2020; 12: e7355
13 Schoeman D, Fielding BC. Coronavirus envelope protein : Current knowledge. Virol J 2019; 16: 69
14 Harapan H, Itoh N, Yufika A. et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020; 13: 667-73
15 Pascarella G, Strumia A, Piliego C. et al. COVID-19 diagnosis and management: A comprehensive review. J Intern Med 2020; 1-15
16 Fung TS, Liu DX. Human Coronavirus : Host-Pathogen Interaction. Annu Rev Microbiol 2019; 73: 529-557
17 Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020; 215: 108427
18 Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci 2020; 252: 117652
19 Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020; 20: 339-341
20 Zhong J, Tang J, Ye C. et al. The immunology of COVID-19: Is immune modulation an option for treatment?. Lancet Rheumatol 2020; 913: 1-9
21 Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87: 281-286
22 Sanders JM, Monogue ML, Jodlowski TZ. et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review. JAMA-J Am Med Assoc 2020; 323: 1824-36
23 Sarma P, Prajapat M, Avti P. et al. Therapeutic options for the treatment of 2019-novel coronavirus : An evidence-based approach. Indian J Pharmacol 2020; 52: 1-5
24 Guo Y, Cao Q, Hong Z. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- an update on the status. Military Med Res 2020; 7: 11
25 Wu R, Wang L, Kuo HCD. et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Reports 2020;
26 Ford N, Vitoria M, Rangaraj A. et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: Initial assessment. J Int AIDS Soc 2020; 23: e25489
27 Ciotti M, Angeletti S, Minieri M. et al. COVID-19 Outbreak: An Overview. Chemotherapy 2020;
28 Cherian SS, Agrawal M, Basu A. et al. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res 2020; 151: 160-171
29 Prajapa M, Sarma P, Shekhar N. et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020; 52: 56-65
30 Cheng VCC, Lau SKP, Woo PCY. et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20: 660-694
31 Dong L, Shasha H, Gao J. Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). Drug Discov Ther 2020; 14: 58-60
32 Asai A, Konno M, Ozaki M. et al. COVID-19 Drug Discovery Using Intensive Approaches. Int J Mol Sci 2020; 21: 2839
33 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71
34 Caly L, Druce JD, Catton MG. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787
35 Joshi T, Joshi T, Sharma P. et al. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur Rev Med Pharmacol Sci 2020; 24: 4529-4536
36 Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635-664
37 Maestri E, Formoso G, Da Cas R. et al. Vitamin D and Coronavirus: A New Field of Use?. Recenti Prog Med 2020; 111: 253-256
38 Protective Effect of Aspirin on COVID-19 Patients (PEAC) 19-6-2020. Available from URL: https://clinicaltrials.gov/ct2/show/NCT04365309; (accessed on 19/06/2020)
39 Barros RO, Junior FLCC, Pereira WS. et al. Interaction of drug candidates with various SARS-CoV-2 receptors: An in silico study to combat COVID-19. Chem Rxiv 2020; 1-15
40 Arya R, Das A, Prashar V. et al. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. Chem Rxiv 2020;
41 Narkhede RR, Cheke RS, Ambhore JP. et al. The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2. EJMO Eurasian. J Med Oncol 2020; 4: 185-195
42 Peele KA, Potla C, Srihansa T. et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2 : A computational study. Inform Med Unlocked 2020; 19: 100345;
43 Sepay N, Hoque AA, Mondal R. et al. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme. Struct Chem 2020; 13: 1-10
44 Zhang L, Lin D, Sun X. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020; 368: 409-412
45 Dhama K, Khan S, Tiwari R. et al. COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics and therapeutics. Hum Vacc Immunother 2020;
46 Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from Other Corona Strains. Infect Dis Ther 2020; 9: 255-274